Corvus Pharmaceuticals
CRVS
45 hedge funds and large institutions have $91M invested in Corvus Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 17 closing their positions.
1.44% less ownership
Funds ownership: 84.44% → 83% (-1.4%)
9% less capital invested
Capital invested by funds: $99.5M → $91M (-$8.58M)
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
22% less funds holding
Funds holding: 58 → 45 (-13)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
65% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$2.61M |
| 2 |
O
OrbiMed
New York
|
+$2.34M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$234K |
| 4 |
Millennium Management
New York
|
+$219K |
| 5 |
Renaissance Technologies
New York
|
+$201K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.31M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.05M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$798K |
| 4 |
State Street
Boston,
Massachusetts
|
-$751K |
| 5 |
JP Morgan Chase
New York
|
-$393K |
CRVS Hedge Fund Activity: Q2 2019 in Review
45 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q2 2019, worth a combined $91M — down 8.6% from $99.5M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CRVS and 6 opened new positions — a net loss of 11 holders — while 16 trimmed existing stakes and 14 added.
The largest buyer was BVF Inc, adding an estimated $2.61M. The largest seller was BlackRock, cutting an estimated $2.31M.
- 45 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q2 2019, down from 58 in Q1 2019.
- Funds reported $91M of Corvus Pharmaceuticals stock for Q2 2019, down 8.6% quarter-over-quarter.
- 6 funds opened new Corvus Pharmaceuticals positions in Q2 2019 and 17 closed out, a net change of -11 holders.
- The largest Corvus Pharmaceuticals buyer in Q2 2019 was BVF Inc, an estimated $2.61M added.
- The largest Corvus Pharmaceuticals seller in Q2 2019 was BlackRock, an estimated $2.31M sold.
Based on aggregated 13F filings for Q2 2019.